Funding profile · Veterinary oncology
Gamgee
A pre revenue, pre clinical readout company that raised a reported $4 million seed round five months after its founding case went viral. No SEC filing for the round has been found. Here is what is on the record and what is company reported.
Data as of September 25, 2026. Company-reported figures are labeled.
Rounds at a glance
| When | Round | Amount | Investors | Source |
|---|---|---|---|---|
| 2026 | Y Combinator, Summer 2026 | Not disclosed | Y Combinator | YC data |
| Aug 17, 2026 | Seed round, announced at launch | $4.0M | Led by Founders Fund; also Celine Halioua (Loyal), Steve Eidelman (Modern Animal), Arash Ferdowsi (Dropbox), Gokul Rajaram | Company release |
What the filings show
No Form D or other SEC filing was found under the name “Gamgee” or “Gamgee Technologies” on EDGAR as of September 25, 2026. A search of the SEC company database turns up only one prior registrant named Gamgee, Inc., CIK 0001562526 of Palo Alto, California, which filed three Form D notices in 2013 and 2014. That filer predates this company’s 2026 founding by more than a decade and its address, filing dates and public record show it is a different, unrelated entity. It is not treated as this company’s filing history here.
A Form D notice is due within 15 days of a round’s first sale of securities under Regulation D. Companies that raise under other exemptions, such as Section 4(a)(2), or that have not yet had a qualifying first sale at the time of this review, may show no Form D at all without that meaning no money moved. Given the round was announced on August 17, 2026, a filing tied to that sale, if one is made under Regulation D, would not necessarily have appeared yet by this review date.
Reading the public record
- The $4 million figure comes entirely from the company and press, not from a filing.GlobeNewswire’s launch release, and independent write-ups in Medical Daily, PYMNTS.com, Dealroom.co and 36Kr, all report a $4 million seed led by Founders Fund. No SEC document corroborates the amount, the lead investor, or the closing date.
- The named backers are a mix of institutional and individual money.Founders Fund is named as lead. The other four names disclosed, Celine Halioua, Steve Eidelman, Arash Ferdowsi and Gokul Rajaram, are individuals rather than funds, which is consistent with an angel-heavy seed round even though no per-investor amounts were disclosed.
- Dealroom’s own analysis flags the size against the evidence.Dealroom.co describes the $4 million round as sitting in the 80th percentile for size among comparable deals, and notes that is a sizeable round for a company whose only proof point is a single, unblinded animal case that ended in relapse.
- The founding entity’s identity is not fully settled in public sources.Gamgee’s Y Combinator founder bio describes Paul Conyngham as “Founder at Gamgee Technologies (YC S26),” while the company’s own press materials and website use the name Gamgee throughout. No EDGAR filer named Gamgee Technologies was found either.
- No non-dilutive funding, such as a government or research grant, was found on the record.Unlike device or diagnostics companies that often carry NIH or NSF grant history, no NIH, NSF or equivalent Australian public funding record for Gamgee or Conyngham’s earlier work on Rosie’s case was found in this review.
Commercial signals
| Signal | Detail | Source type |
|---|---|---|
| Regulatory | No FDA or USDA product authorization found. Company says it is pursuing a USDA patient-specific veterinary biologic pathway. | Not found |
| Clinical trial | Trial enrolling in eastern Australia, target about 30 dogs, run with UNSW, University of Queensland and the Garvan Institute. No public trial registry listing found. | Company-stated |
| Revenue or paying customers | None disclosed. Trial participants receive the investigational vaccine at no cost. | Company-stated |
| Accelerator | Y Combinator, Summer 2026 batch, primary partner listed as Tyler Bosmeny. | YC data |
| Founding narrative reach | Company states its founding case drew “over a billion impressions,” and it was shared by OpenAI chief executive Sam Altman in March 2026. | Company-stated |
What to watch
- Whether a Form D appears for the $4 million round, and whether its filed amount matches the announced figure.
- Whether the legal entity name settles as Gamgee, Inc. or Gamgee Technologies, Inc. in any future filing.
- A Series A or additional seed extension, and whether institutional investors beyond Founders Fund are disclosed.
- Whether the company publishes trial results or registers its Australian study publicly.
The Gamgee story on Healthcare DiscoveryHealthcare Discovery
Related companies
Sources
- Public recordEDGAR company search, “Gamgee”
- Public recordEDGAR company search, “Gamgee Tech”
- Public recordForm D filings, Gamgee, Inc., CIK 0001562526 (unrelated Palo Alto filer, 2013 to 2014)
- CompanyOne Dog’s Legacy Becomes GAMGEE
- CompanyGamgee company profile and launch post
- IndependentRosie’s Cancer Came Back After Her AI-Designed Vaccine, and Her Owner Just Raised $4 Million
- IndependentOne Dog’s Cancer Vaccine Just Became a Real Company
- IndependentFounders Fund backs Gamgee’s $4M seed for AI-designed dog cancer vaccines
- Independent3 Months After Dog Rosie Passed Away, Her Medical Records Spawned an AI Medical Startup
- IndependentAI-powered dog cancer vaccine startup Gamgee secures $4M in seed funding
- IndependentOf course the ChatGPT dog cancer vaccine spawned a startup
Compiled from SEC and other public records and published reports as of September 25, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date. Healthcare Venture Capital Fund holds no position in Gamgee. This page is not an offer to sell or a recommendation to buy any security.